[HTML][HTML] Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression …
MAJ Gorris, LL van der Woude, LI Kroeze… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICI) can lead to long-term responses in patients
with metastatic melanoma. Still many patients with melanoma are intrinsically resistant or …
with metastatic melanoma. Still many patients with melanoma are intrinsically resistant or …
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic …
Abstract Background Ipilimumab (Ipi) improves the survival of advanced melanoma patients
with an incremental long-term benefit in 10–15% of patients. A tumor signature that …
with an incremental long-term benefit in 10–15% of patients. A tumor signature that …
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
R Jamal, R Lapointe, E Cocolakis, P Thébault… - … for immunotherapy of …, 2017 - Springer
Background Checkpoint blockade with ipilimumab provides long-term survival to a
significant proportion of patients with metastatic melanoma. New approaches to increase …
significant proportion of patients with metastatic melanoma. New approaches to increase …
Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma
N Asher, G Ben-Betzalel, S Lev-Ari… - Cancers, 2020 - mdpi.com
Background: Immunotherapy has drastically changed the outlook for melanoma patients
over the past decade. Specifically, the dual blockade of immune checkpoints using …
over the past decade. Specifically, the dual blockade of immune checkpoints using …
High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma …
N Chakravarti, D Ivan, VA Trinh, IC Glitza… - Melanoma …, 2017 - journals.lww.com
Ipilimumab, a fully human monoclonal antibody against cytotoxic T-lymphocyte-associated
antigen 4 (CTLA-4), is the first immune checkpoint inhibitor approved for the treatment of …
antigen 4 (CTLA-4), is the first immune checkpoint inhibitor approved for the treatment of …
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
O Hamid, H Schmidt, A Nissan, L Ridolfi… - Journal of translational …, 2011 - Springer
Background Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-
lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III …
lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III …
Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
Background Patients with metastatic melanoma have variable responses to combination
ipilimumab and nivolumab. The objectives of this study were to examine the patterns of …
ipilimumab and nivolumab. The objectives of this study were to examine the patterns of …
Biomarkers on melanoma patient T cells associated with ipilimumab treatment
W Wang, D Yu, AA Sarnaik, B Yu, M Hall… - Journal of translational …, 2012 - Springer
Background Ipilimumab induces long-lasting clinical responses in a minority of patients with
metastatic melanoma. To better understand the mechanism (s) of action and to identify novel …
metastatic melanoma. To better understand the mechanism (s) of action and to identify novel …
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization
Immune checkpoint inhibitors, including ipilimumab (IPI), achieve a clinical benefit in a small
proportion of melanoma patients highlighting the need to investigate predictive biomarkers …
proportion of melanoma patients highlighting the need to investigate predictive biomarkers …
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Abstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical
management of melanoma. However, not all patients respond, and current biomarkers …
management of melanoma. However, not all patients respond, and current biomarkers …
相关搜索
- melanoma patients ipilimumab therapy
- metastatic patients features of melanomas
- melanoma patients tumor samples
- ipilimumab and nivolumab metastatic melanoma
- patients with melanoma response patterns
- patients with melanoma acquired resistance
- world outcomes metastatic melanoma
- metastatic patients durable remission
- melanoma patients phospho akt
- melanoma patients associated antigen
- melanoma patients ctla 4
- nivolumab in patients metastatic melanoma